QuidelOrtho Enhances Board with Strategic Appointments of Chiminski and Huennekens

QuidelOrtho Fortifies Its Board with Strategic Appointments

QuidelOrtho Corporation, a prominent player in the in vitro diagnostic technology sector, announces the strategic appointments of John R. Chiminski and R. Scott Huennekens to its board of directors, effective December 6, 2024. This decision underscores the company’s commitment to enhancing its governance with seasoned professionals possessing extensive experience in healthcare, biopharma, and MedTech. The appointments reflect a deliberate strategy to cultivate a board that can navigate the complexities of the evolving diagnostic landscape while driving growth and innovation.

Chiminski, the former CEO of Catalent, brings a wealth of knowledge in medical diagnostics and pharmaceuticals. His leadership at Catalent, where he successfully transformed the company into a standalone public entity, is a testament to his capabilities in fostering business growth. Additionally, during his tenure at GE Medical Diagnostics, he played a pivotal role in generating $1.9 billion in sales, highlighting his proficiency in scaling operations and enhancing market presence. His background positions him well to contribute to QuidelOrtho’s aspirations to expand its footprint in the diagnostic sector.

Huennekens complements Chiminski’s expertise with his rich experience in the MedTech arena. Having led over 20 startups and served as CEO of Verb Surgical—an innovative collaboration between tech giant Google and healthcare leader Johnson & Johnson—Huennekens brings a fresh perspective to the board. His track record in pioneering medical technologies aligns seamlessly with QuidelOrtho’s mission to enhance patient outcomes through cutting-edge diagnostic solutions. Brian J. Blaser, President and CEO of QuidelOrtho, emphasizes that the diverse insights of Chiminski and Huennekens will be instrumental in advancing the company’s transformational strategy and improving financial performance.

The appointments of Chiminski and Huennekens mirror QuidelOrtho’s ongoing commitment to fostering a robust board capable of driving shareholder value. As the company faces the dynamic challenges of the diagnostic testing industry, bringing in leaders with proven records of growth and innovation is a strategic maneuver. This proactive approach not only positions QuidelOrtho to better address market demands but also enhances its ability to leverage innovative technologies that can significantly improve patient care.

In addition to these appointments, QuidelOrtho continues to focus on advancing its portfolio of diagnostic solutions. By integrating the expertise of its new board members, the company aims to enhance its strategic initiatives and deliver on its commitment to innovation in the healthcare sector. This alignment of leadership is expected to reinforce QuidelOrtho’s mission of improving health outcomes through reliable and advanced diagnostic technologies.